Purpose:
The British Columbia Cancer Agency radiotherapy (RT) program started the Prospective Outcomes and Support Initiative (POSI) at all six centres in 2013 to collect and utilize patient reported outcomes (PROs) for patients receiving palliative intent RT. In 2015 it expanded to patients receiving curative intent RT, starting with the gynecological (gyne) tumour group. We sought to describe the success in expanding to non-palliative sites. Methods and Materials: Five validated questionnaires, the EPIC Bowel 2 (2002), EPIC Urinary 2 (2002), PRO-CTAE GI toxicity, EORTC QLQ CX24, and the EQ5DL were selected as the PROs of interest by the gyne tumour group. The questionnaires were converted to tablet format, and data was entered directly by patients via tablet at time of RT, and each subsequent follow up (FU). Some centres choose to also administer the questions weekly during RT, which is categorized as FU below in comparing scores to baseline. The results of the questionnaires were made available immediately to Radiation Oncologists, viewable in the RT electronic medical record, and in a local intranet POSI Portal. Descriptive Statistics were used to present accrual data and results of the PRO questionnaires. Results: From March 2015 to January 2016, 480 gyne patients were approached by POSI on 1007 occasions (i.e. baseline, on treatment, or FU), with a 97% response rate. However, not all six British Columbia Cancer Agency centres participated at that time, with Vancouver and Victoria starting in March, Abbotsford in July, Kelowna in August, while Surrey and Prince George have not yet participated. The mean (and standard deviation) scores of the EPIC Bowel, EPIC Urinary, PRO-CTAE GI, EORTC QLQ CX24, and EQ5DL were 8.9 (9.4), 6.1 (7.3), 2.9 (3.4), 2.8 (3.5), and 8.8 (3.2), respectively, with significantly (p < 0.05) worse scores at FU compared to baseline for each questionnaire, except the EQ5DL (p = 0.62). Of the 24 patients not accrued, 29% were unfit, 21% had not interpreter available, and 50% declined. Among those who declined, 33% did at baseline, 17% at first repeat measure, 25% at second, and 25% at the third or later repeat measure. Among the 189 patients who reported PRO on more than one time interval, 72, 37, and 80 patients repeated the PRO 2,3, and > 3 occasions respectively to date. Conclusions: Expansion of POSI to collect PRO in a radical tumour group appears feasible, though there have been barriers to expansion to all six British Columbia Cancer Agency centres, which will be explored. Despite the use of five validated questionnaires totaling 49 questions, the accrual rate is exceptional, and appears feasible weekly during radiotherapy. Expansion to other radical tumour sites will be used to test if these results are reproducible. Future plans are to test the impact of providing PRO data to clinicians, and to make gyne PRO data available for research and quality improvement initiatives. 
The EORTC 22881 boost trial showed a substantial benefit of delivering a radiotherapy boost to the tumour bed (RTB) in women aged 40 years and younger, with an improvement in 10-year local relapse-free survival (LRFS) of 10%. However, this trial was carried out in an era where pre-menopausal women did not receive adjuvant hormone therapy (HT). We sought to determine how the use of HT and RTB changed in a populationbased cancer care program in response to new practice guidelines, and whether this had an impact on LRFS. We also set out to determine whether the anticipated benefit of a RTB for young women was observed in the era of routine HT. Methods and Materials: A provincial database was used to identify all women 40 years and younger with breast cancer that met the inclusion criteria of the EORTC 22881 trial: treated with whole breast radiotherapy after breast conserving surgery, margin negative (not at ink), and Stage I and II. The percentages of women receiving HT and RTB were compared across three Eras that were defined, a priori, with a three-month delay allowing for implementation of the practice changes: Era 1 (pre-HT, preboost) January 1996-September 1998; Era 2 (HT, pre-boost) January 1999 -September 2001; Era 3 (HT and boost) January 2002 -September 2004. LRFS was calculated using the KaplanMeier method and the three eras compared using a log rank test. Factors significant at < 0.3 on univariate analysis were included with Era in a multivariable (MVA) Cox model.
Results:
The study included 411 patients: 130 in Era 1, 142 in Era 2, and 139 in Era 3. The use of adjuvant HT increased over time, with 8% use in Era 1, 45% in Era 2 and 54% in Era 3 (p = < 0.001) For estrogen receptor (ER) positive cancers, HT use was higher: 13% in Era 1, 68% in Era 2 and 82% in Era 3 (p = < 0.0001). The CARO 2016 S7 _________________________________________________________________________________________________________ use of RTB after adjuvant breast radiotherapy was 38% in Era 1, 29% in Era 2 and 76% in Era 3 (p < 0.001). Ten-year LRFS was 85.3% in Era 1, 93.9% in Era 2 and 91.9% in Era 3. On MVA there was a significant decrease in relapse going from Era 1 (pre-HT, pre-boost) to Era 2 (HT, no boost) (HR 2.2, p = 0.03), but no change in relapse from Era 2 (HT, no boost) to Era 3 (HT and boost) (HR 1.0, p = 0.97). For LRFS across all three eras, there was no significant difference for patients that received a boost (92.9%) and those that did not (88.6%, p = 0.31) but there was a significant improvement for ER-positive patients that received HT (91.8% versus 81.6%, p = 0.01). Conclusions: This study showed that new breast cancer therapies were adopted swiftly in response to new clinical practice guidelines. The introduction of HT was associated with an 8.6% improvement in ten-year LRFS. However, for a population of patients that was routinely prescribed HT, no improvement in LRFS was observed with the addition of routine RTB. RTB causes toxicity and offers no survival benefit; its routine use should be re-evaluated in the HT era. Purpose: To determine whether DIBH produced a clinically meaningful reduction in pulmonary dose in comparison to free breathing (FB) during adjuvant locoregional radiation (RT) for right-sided breast cancer. Methods and Materials: Thirty women with Stages 0-I left-sided breast cancer and who had both DIBH and FB CT scans as part of standard care were included. The right-sided IMC nodes were contoured according to ESTRO guidelines on DIBH and FB scans, with care taken to ensure comparability between scans. A fourfield, modified-wide tangent RT plan was developed on each scan to include the right breast and full regional nodes, including a minimum dose of 80% to the IMC volume. The junction between the supraclavicular and tangent fields was at the inferior extent of the ossified medial clavicle. Treatment plans were calculated in Eclipse using the Acuros algorithm version 11. FB and DIBH plan metrics were compared using Wilcoxon-signed rank testing. Results: IMC coverage was equivalent between DIBH and FB plans; V80 was 100% on both plans and D100 was 39.2 and 39.5 Gy for DIBH and FB, respectively. Twenty-one patients (70%) had ≥ 5% reduction in ipsilateral lung V20 with DIBH compared to FB. The average ipsilateral lung V20 decreased by 7.8% (range: 0 to 20%; p < 0.001) and the mean lung dose decreased by 3.4 Gy with DIBH (range: -0.2 to 9.1; p < 0.001). The right lung absolute V20 Gy gain from DIBH was larger among 15 patients with the highest V20 compared to 15 patients with the lowest V20 on FB (10.1% versus 5.6% respectively; p = 0.01). There was a mean reduction of 42.3 cc (range: 0 to 178.9; p < 0.001) in the volume of liver receiving 50% of the prescription dose. The differences in mean heart doses were statistically significant, but not likely clinically significant: MHD was 0.88 Gy (range: 0.67 to 1.27) and 1.00 Gy (range: 0.75 to 1.48) (p < 0.001) for DIBH and FB, respectively. Conclusions: DIBH reduced mean ipsilateral lung V20 by 7.8% and mean lung dose by 3.4 Gy. For some patients, the volume of liver receiving ≥ 25 Gy can also be reduced with DIBH. DIBH should be available as a treatment strategy to reduce right lung V20 without compromising IMC or supraclavicular nodal coverage for patients with right-sided breast cancer during locoregional RT. This strategy can be advantageous in cases where the ipsilateral V20 on FB approaches 30%, a value that prompts many radiation oncologists to exclude IMCs from the RT volume.
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